SynthesisJournal of neuro-oncology2016
Predictors of recurrence in the management of chordoid meningioma.
Synthesis in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Prognostic stratification of chordoid meningiomas: the role of chromosome 1p/22q Loss.Acta neuropathologica communications · 2026Article
- TERT promoter C250T mutation in a recurrent cervical chordoid meningioma: a unique case report.World journal of surgical oncology · 2025Article
- Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.Cureus · 2025Article
- The medial transorbital approach in cranioendoscopic skull base tumor resections for locally advanced tumors.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2024Article
- Lateral ventricle chordoid meningioma presenting with inflammatory syndrome in an adult male: A case report.Experimental and therapeutic medicine · 2023Article
- Unilateral Orbitopathy Caused by Skull Base Chordoid Meningioma.Diagnostics (Basel, Switzerland) · 2023Article
- Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management.Acta neuropathologica communications · 2022Article
- Clinical features, radiological findings, and prognostic factors for primary intracranial chordoid meningioma.Frontiers in neurology · 2022Article
- A Case of Tuberculum Sellae Chordoid Meningioma Treated via Extended Endoscopic Endonasal Trans-sphenoidal Surgery.NMC case report journal · 2020Article
- Clinial Features, Individualized Treatment and Long-Term Surgical Outcomes of Skull Base Meningiomas With Extracranial Extensions.Frontiers in oncology · 2020Article
- Primary Pulmonary Chordoid Meningioma.The Korean journal of thoracic and cardiovascular surgery · 2018Article
- Predictors of early progression of surgically treated atypical meningiomas.Acta neurochirurgica · 2018Article
- Chordoid meningioma: a clinico-pathological study of an uncommon variant of meningioma.Journal of neuro-oncology · 2018Article
- Clinicopathological characteristics and prognostic factors of atypical meningiomas with bone invasion: a retrospective analysis of nine cases and literature review.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Management of chordoid meningiomas (CMs) is complicated by high rates of recurrence, particularly following subtotal resection. Optimal management is not established given the paucity of published experience. To identify prognostic factors for recurrence following resection, the authors conducted the largest systematic review of CMs to date. A comprehensive search on MEDLINE (OVID and Pubmed), Scopus, Embase, and Web of Science utilizing the search terms "chordoid" AND "meningioma" was performed to identify all reports of pathologically confirmed intracranial CMs. A total of 221 patients were included, comprising 120 females and 101 males. Mean age, MIB-1/Ki67, and tumor size was 45.5 years, 4.3% (range 0.1-26.6%), and 4.1 cm (range 0.8-10 cm), respectively. 5-, and 10- year progression free survival was 67.5 and 54.4%, respectively. Gross total resection (GTR) and subtotal resection was achieved in 172 and 48 patients, respectively. Adjuvant radiotherapy (RT) was given to 30 patients. Multivariate analysis found GTR was strongly correlated with decreased recurrence rates (HR 0.04, p = <0.0001), while higher MIB-1 labeling index (≥5 vs <5%) was associated with increased recurrence (HR 7.08; p = 0.016). Adjuvant RT, age, gender, and tumor location were not associated with recurrence. GTR resection is the strongest predictor of tumor control, and should be the goal to minimize local progression. Additionally, higher MIB-1 labeling was associated with increased rates of tumor recurrence. Tumors that are subtotally resected or demonstrate higher MIB-1 are at greater recurrence and warrant consideration for RT and close long term follow up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.